The status of the TP53 gene is a critical factor in cancer prognosis. In general, tumors with wild-type p53 have a better prognosis compared to those with mutant p53. The presence of specific p53 mutations can be associated with more aggressive disease, higher rates of metastasis, and reduced overall survival. Therefore, assessing p53 status is essential for prognostication and can guide therapeutic decision-making.
